RESUMO
Iron deficiency anemia (IDA) and cystoisosporosis are the most common clinical conditions of fast-growing piglets. Until now, IDA and cystoisosporosis have been managed by intramuscular injection of iron complexes (such as dextran or gleptoferron) and oral administration of toltrazuril. Recently, a new combination product containing toltrazuril and gleptoferron for intramuscular application (Forceris®) has been registered. The objective of this study was to compare the pharmacokinetic profiles of toltrazuril and its main metabolite, toltrazuril sulfone, following a single oral (Baycox®) or intramuscular (Forceris®, a toltrazuril-iron combination product) administration at 20 mg/kg to young suckling piglets. The orally treated piglets were also supplemented with iron (Gleptosil®), and the hematinic activities were compared. Piglets in both groups received comparable doses. The peak concentration (Cmax) of toltrazuril after intramuscular administration was 11% lower than that after oral administration (p = .376). However, the exposure to toltrazuril (AUC) was significantly increased (40% higher) when toltrazuril was administered intramuscularly (p = .036). The Cmax and AUC values of the active metabolite, toltrazuril sulfone were 39% and 34% higher, respectively, after intramuscular administration (p = .007 and 0.008, respectively). Piglets in both groups were properly protected against IDA. In conclusion, a higher relative bioavailability of toltrazuril is observed when toltrazuril is administered intramuscularly.
RESUMO
BACKGROUND: The health and productivity of dairy goats continue to be impacted by gastrointestinal nematodes (GIN) and lungworms (LW). Eprinomectin (EPN) is frequently selected for treatment because it is generally effective and does not require a milk withdrawal period. However, some factors, such as lactation, can have an impact on EPN pharmacokinetics and potentially its efficacy. To evaluate whether this can alter the efficacy of Eprecis® 2%, an eprinomectin injectable solution, a study was performed in lactating goats using the dose currently registered in cattle, sheep and goats (0.2 mg/kg). METHODS: This study was a blinded, randomized, controlled trial performed according to the VICH guidelines. Eighteen (18) worm-free lactating goats were included and experimentally challenged on day 28 with a mixed culture of infective gastrointestinal and lung nematode larvae (Haemonchus contortus, Trichostrongylus colubriformis, Teladorsagia circumcincta, Dictyocaulus filaria). At D-1, fecal samples were collected to confirm patent infection in all animals. On D0, the goats were randomly allocated into two groups of nine goats; group 1 was treated with Eprecis® 2% at 0.2 mg/kg BW by subcutaneous injection, while group 2 remained untreated. Fecal samples for egg counts were collected from all animals on days 3, 5, 7, 9, 11 and 14. On D14, all goats were killed, and the abomasum, small intestine and lungs were removed, processed and subsampled to record the number and species of worms. RESULTS: The treatment was well tolerated. After treatment, the arithmetic mean FEC decreased in the treated group and remained < 5 EPG until the end of the study, while the arithmetic mean FEC in the control group remained > 849.0 EPG. At D14, goats in the treated group had very limited or zero total worm counts, whereas all animals from the control group had a high worm burden. The measured efficacy was 100.0% against H. contortus and T. colubriformis, 99.9% against T. circumcincta and 98.0% against D. filaria. CONCLUSIONS: Eprinomectin (Eprecis®, 20 mg/ml), administered at the label dose (0.2 mg/kg), is highly effective against gastrointestinal nematodes and lungworms in lactating goats.
Assuntos
Fezes , Doenças das Cabras , Cabras , Ivermectina , Lactação , Infecções por Nematoides , Animais , Ivermectina/análogos & derivados , Ivermectina/administração & dosagem , Ivermectina/farmacocinética , Ivermectina/uso terapêutico , Doenças das Cabras/tratamento farmacológico , Doenças das Cabras/parasitologia , Feminino , Infecções por Nematoides/veterinária , Infecções por Nematoides/tratamento farmacológico , Infecções por Nematoides/parasitologia , Fezes/parasitologia , Lactação/efeitos dos fármacos , Contagem de Ovos de Parasitas/veterinária , Injeções Subcutâneas/veterinária , Anti-Helmínticos/administração & dosagem , Anti-Helmínticos/uso terapêutico , Anti-Helmínticos/farmacocinética , Nematoides/efeitos dos fármacos , Gastroenteropatias/veterinária , Gastroenteropatias/parasitologia , Gastroenteropatias/tratamento farmacológico , Pulmão/parasitologiaRESUMO
Piglet coccidiosis is a parasitic disease caused by the protozoan Cystoisospora suis, which is regarded as the most prevalent gastrointestinal parasite in intensive pig farms. Despite the availability of highly effective chemo-metaphylaxis (toltrazuril), coccidiosis is still prevalent in European and other countries. We conducted a cross-sectional study on swine farms in Brazil, to assess the prevalence of Cystoisospora suis in fecal samples and determined the associated factors. In total, 666 litters from 50 farms were sampled twice within one week between samplings (mean age at sampling: 10.75 and 17.7 days). Of 666 litters, 225 (33.8%) were positive at least once, and the expected within farm prevalence of C. suis oocysts was 32.9% (25.4-41.3%; 95% confidence interval). Oocysts were more prevalent in fecal samples collected from farms with diarrhea (odds ratio = 6.75). The room temperature was also positively associated with oocyst detection; a one-degree increase in room temperature increased the chance of a litter being positive by 23.2%. Up-to-date, this is the most comprehensive technical evidence of factors associated with C. suis infection in Brazilian industrial piglet farms.
Assuntos
Coccidiose , Isospora , Sarcocystidae , Doenças dos Suínos , Animais , Suínos , Brasil/epidemiologia , Prevalência , Estudos Transversais , Animais Lactentes/parasitologia , Doenças dos Suínos/epidemiologia , Doenças dos Suínos/parasitologia , Coccidiose/epidemiologia , Coccidiose/veterinária , Coccidiose/parasitologia , OocistosRESUMO
Oedema disease of weaned piglets is caused by shigatoxigenic Escherichia coli (STEC), typically harbouring the stx2e gene and F18 adhesins. The aim of this study was to assess the effect of a commercially available oedema disease vaccine on the zootechnical performance, mortality and individual antibiotic treatment in a herd, in which non-typical STEC strains without F18 adhesin have been identified. The zootechnical performance (average daily gain, total weight gain), mortality and individual antibiotic treatment were compared between vaccinated and non-vaccinated control piglets in a monocentric field efficacy study, which was performed using two groups in a parallel, randomised design. A significantly higher average daily gain and total weight gain were recorded in the vaccinated piglets in comparison to the controls. The lower morbidity, mortality and antibiotic treatment in piglets in the vaccine group were not statistically significant. As a conclusion, the positive effect of the vaccination was confirmed in the herd with prevalent STEC not harbouring F18 adhesin. The vaccine was, therefore, also effective against oedema disease caused by such unusual STEC isolates, under the conditions of this study.
RESUMO
Piglet coccidiosis due to Cystoisospora suis is a major cause of diarrhea and poor growth worldwide. It can effectively be controlled by application of toltrazuril (TZ), and oral formulations have been licensed for many years. Recently, the first parenteral formulation containing TZ in combination with iron (gleptoferron) was registered in the EU for the prevention of coccidiosis and iron deficiency anemia, conditions in suckling piglets requiring routine preventive measures. This study evaluated the absorption and distribution of TZ and its main metabolite, toltrazuril sulfone (TZ-SO2), in blood and intestinal tissues after single oral (20 mg/kg) or single intramuscular (45 mg/piglet) application of TZ. Fifty-six piglets were randomly allocated to the two treatment groups. Animals were sacrificed 1-, 5-, 13-, and 24-days post-treatment and TZ and TZ-SO2 levels were determined in blood, jejunal tissue, ileal tissue, and mixed jejunal and ileal content (IC) by high performance liquid chromatography (HPLC). Intramuscular application resulted in significantly higher and more sustained concentrations of both compounds in plasma, intestinal tissue, and IC. Higher concentrations after oral dosing were only observed one day after application of TZ in jejunum and IC. Toltrazuril was quickly metabolized to TZ-SO2 with maximum concentrations on day 13 for both applications. Remarkably, TZ and TZ-SO2 accumulated in the jejunum, the primary predilection site of C. suis, independently of the administration route, which is key to their antiparasitic effect.
Assuntos
Coccidiostáticos/metabolismo , Coccidiostáticos/farmacocinética , Mucosa Intestinal/metabolismo , Sulfonas/metabolismo , Sulfonas/farmacocinética , Triazinas/metabolismo , Triazinas/farmacocinética , Administração Oral , Animais , Peso Corporal/efeitos dos fármacos , Coccidiose/prevenção & controle , Coccidiose/veterinária , Coccidiostáticos/administração & dosagem , Íleo/metabolismo , Injeções Intramusculares , Jejuno/metabolismo , Sulfonas/administração & dosagem , Suínos , Doenças dos Suínos/prevenção & controle , Triazinas/administração & dosagemRESUMO
The objective was to investigate the effect of injectable eprinomectin on milk yield and quality of dairy ewes naturally infected with gastrointestinal nematodes when grazing in communal pastures. Onehundred and fifty (150) clinically healthy adult lactating ewes, equally selected from 3 farms, were included in the study. On day -7, the ewes on each farm were randomly allocated into 2 equal groups of 25 animals (n=50): Control group (C) and Treated group (T). On day 0, ewes in group T were given a single subcutaneous injection of eprinomectin at a dose rate of 0.2 mg/kg bodyweight. Ewes in group C were left untreated during the whole experiment. Ewes in group T with a fecal egg count (FEC) >300 eggs per g on day +60 were treated again. Fecal samples were individually collected on days -7, 0, +30, +60, +90, +120 for FEC estimations and coprocultures. On days -7, 0, +30, +60 and +90, individual milk yield (MY) was recorded using ICAR approved volumetric milk meters. Energy corrected milk yield (ECMY) for 6% fat was also calculated. Moreover, individual milk samples were collected on each day for determination of chemical composition [fat (F%), protein (P%) and lactose (L%) content] and somatic cell counts (SCC). On each day, individual fat and protein yield (FY and PY, respectively) were calculated. Total lactation MY, total ECMY, total FY and total PY were computed. The most prevalent parasite at pre-treatment and post-treatment days was Haemonchus spp. The overall efficacy on days +30 and +90 was 97.27 % and 98.80 %, respectively. In two out of the three farms, 80 % and 91.3 % of T ewes received a second treatment on day +60, due to high parasitic burden. Treatment had a significant effect (P=0.033) on MY with an average benefit of 8%. No significant effects of treatment were observed on the other parameters, although values were constantly numerically higher for treated ewes compared to control ones. In this field trial, injectable eprinomectin had a high overall efficacy and a beneficial effect on daily milk yield.
Assuntos
Antinematódeos/administração & dosagem , Ivermectina/análogos & derivados , Leite/química , Leite/metabolismo , Infecções por Nematoides/veterinária , Doenças dos Ovinos/parasitologia , Animais , Feminino , Trato Gastrointestinal/parasitologia , Ivermectina/administração & dosagem , Infecções por Nematoides/parasitologia , Distribuição Aleatória , Ovinos , Carneiro DomésticoRESUMO
The protozoan parasite Cystoisospora suis causes diarrhea and reduced weight gain in suckling piglets. Infections occur in the first days of life; it is transient but can lead to dysbiosis, exacerbating disease and increasing mortality. Cystoisosporosis is effectively controlled by toltrazuril treatment; however, alterations of the gut microbial composition upon infection and treatment have not been investigated. This study evaluated the development of fecal microbiota of C. suis infected piglets in response to treatment with toltrazuril. Thirty-eight conventional piglets were infected with C. suis on the first day of life (dol 1). Twenty-six of them received either parenteral or oral toltrazuril 2 days later. Fecal samples were collected pre- and post-weaning (dol 1-15 and 31-38) for microbiota analysis using 16S rRNA amplicon sequencing and during dol 5-18 to determine fecal consistency and parasite excretion. All control animals shed parasites at least once and the majority developed diarrhea, while toltrazuril-treated piglets did not excrete parasites and only had low levels of diarrhea. Age-related shifts in the fecal microbiota composition and increase in diversity and species richness were seen until after weaning. Parasite infection disrupted bacterial maturation 2 weeks after infection. Irrespective of the route of administration, fecal communities of piglets in the treated groups clustered separately and were more diverse compared to that of control piglets during the acute phase of infection on dol 11. Control piglet feces showed higher levels of Fusobacteriaceae and Veillonellaceae, while Ruminococcaceae, Lachnospiraceae, S24-7, Clostridiaceae, and Erysipelotrichaceae were more abundant in feces of treated piglets on dol 11. Thereafter, treatment-related effects on the microbial communities were small and mainly detectable on dol 34 (5 days post-weaning), potentially indicating that the oral toltrazuril treatment might have had long-term effects on host physiological responses post-weaning. Irrespective of the administration route, toltrazuril prevented C. suis-related dysbiosis and maintained species richness and diversity on dol 11. In addition to cystoisosporosis prevention, toltrazuril seems to contribute to the stabilization of the gut microbial development during the suckling phase and thus may reduce the need for antibiotics to control infections with secondary bacterial enteropathogens in C. suis-infected suckling piglets.
RESUMO
BACKGROUND: Toltrazuril is frequently administered for the metaphylactic control of piglet cystoisosporosis. In a previous study, the efficacy of parenteral toltrazuril (45 mg/piglet, Group Forceris®) applied on the 2nd day of life (dol), and of oral toltrazuril (20 mg/kg of body weight, Group Baycox®) applied on the 4th dol was evaluated in an experimental model with Cystoisospora suis infection on the 3rd dol (late infection, LI). In a follow-up study, efficacy and safety were evaluated against infections with C. suis on the 1st dol (early infection, EI). Parameters included oocyst excretion and faecal consistency, body weight development, bacteriological examinations and animal health. RESULTS: All control piglets (n = 12) shed oocysts and had diarrhoea, while parasite excretion was completely suppressed in both treatment groups (n = 13 each) and diarrhoea was reduced to a single animal (Forceris® group), resulting in significant differences for these parameters between the treated groups and the controls without significant differences among the treatment groups. No treatment-related adverse events were noted. Body weight gain was reduced in the control group during the acute phase of infection, resulting in significantly lower body weight on the 15th dol. Sows and piglets shed high numbers of Escherichia coli. Clostridium perfringens type A was only detected in low amounts in pooled litter samples. In comparison to the LI study oocyst shedding was more intense in the control animals in EI, while diarrhea was more frequent in LI. In both infection models a high efficacy of toltrazuril in the control of parasitological and clinical outcomes of experimental C. suis infection could be demonstrated. Since in the LI study high numbers of Cl. perfringens type A were detected, it is hypothesized that colonization with these opportunistic pathogens has synergistic effects with C. suis and may explain variable clinical outcomes in untreated animals as well as the sporadic occurrence of diarrhea in toltrazuril-treated piglets. CONCLUSIONS: Parenteral and oral toltrazuril administered on the 2nd or 4th dol is safe and effective against experimental infections with C. suis on the 1st to 3rd dol. The clinical outcome of experimental infections seems influenced by bacterial coinfections.
Assuntos
Coccidiose/veterinária , Ferro/uso terapêutico , Sarcocystidae/efeitos dos fármacos , Doenças dos Suínos/tratamento farmacológico , Triazinas/uso terapêutico , Administração Oral , Animais , Animais Lactentes , Bactérias/isolamento & purificação , Peso Corporal/efeitos dos fármacos , Coccidiose/tratamento farmacológico , Coinfecção , Modelos Animais de Doenças , Combinação de Medicamentos , Fezes/parasitologia , Feminino , Seguimentos , Injeções Intramusculares , Ferro/administração & dosagem , Oocistos/efeitos dos fármacos , Oocistos/isolamento & purificação , Distribuição Aleatória , Suínos , Doenças dos Suínos/parasitologia , Resultado do Tratamento , Triazinas/administração & dosagem , Triazinas/efeitos adversos , Aumento de PesoRESUMO
The anthelmintic activity of an injectable eprinomectin formulation (Eprecis® 20 mg/mL) was evaluated in 150 naturally infected dairy sheep raised in 3 semi-intensive flocks. All ewes were at the same stage of lactation and grazed on natural pastures. Ewes did not receive any anthelmintic treatment for at least 4 months prior to the experiment. In each flock, 50 ewes were selected and randomly allocated to control (C) or treatment (T) groups (n = 25 per group). Groups were balanced according to the ewes' bodyweight (BW) and fecal egg count (FEC) measured seven days before eprinomectin administration (day-7). On study day 0, ewes in group T, received 0.2 mg/kg BW of eprinomectin subcutaneously (Eprecis® 20 mg/mL, Ceva). Ewes in group C were left untreated. Fecal samples were collected on day 0, 7, 14, 21 and 28 post-treatment to assess FEC and for coprocultures. Ewes were weighed on day 0 and 28. Overall and within-flock efficacy of eprinomectin was calculated throughout the experimental period. No local or general adverse reaction after injection was observed. The most prevalent parasite genera were Teladorsagia, Haemonchus and Trichostrongylus. Following treatment, the overall mean FEC of C and T groups differed significantly (P < 0.001). Overall and within-flock efficacy of eprinomectin was 99.8%-100.0% and 99.7%-100.0%, respectively. Contrary to C group, ewes treated with injectable eprinomectin increased their BW during the study (-0.5 kg vs. + 1.5 kg, P < 0.001). In this field study, a single subcutaneous injection of eprinomectin to dairy sheep, at 0.2 mg/kg BW, resulted in excellent curative anthelmintic activity; egg counts remain low for at least 28 days after treatment.
Assuntos
Anti-Helmínticos/uso terapêutico , Helmintíase Animal/tratamento farmacológico , Ivermectina/análogos & derivados , Doenças dos Ovinos/tratamento farmacológico , Animais , Anti-Helmínticos/administração & dosagem , Peso Corporal , Indústria de Laticínios , Fezes/parasitologia , Feminino , Hemoncose/tratamento farmacológico , Hemoncose/prevenção & controle , Hemoncose/veterinária , Haemonchus/efeitos dos fármacos , Helmintíase Animal/prevenção & controle , Injeções Subcutâneas , Ivermectina/administração & dosagem , Ivermectina/uso terapêutico , Contagem de Ovos de Parasitas , Ovinos/parasitologia , Doenças dos Ovinos/parasitologia , Doenças dos Ovinos/prevenção & controle , Resultado do TratamentoRESUMO
Insect resistance mechanisms against pesticides lead to the development and the search of new pesticide combinations in order to delay the resistance. The combination of neonicotinoids with pyrethroids was currently proposed but the mode of action of these compounds at synaptic and extrasynaptic levels needs to be further explored. In the present study, we evaluated the effect of the combination of two insecticides, permethrin and dinotefuran, on cockroach cholinergic synaptic transmission and on isolated cell bodies. We first found that combination of 5 µM permethrin and dinotefuran enhances depolarization of the sixth abdominal ganglion compared to dinotefuran alone, without an inhibition of the spontaneous activity. However, a pretreatment with 1 µM dinotefuran or permethrin before bath application of the mixture inhibits the ganglionic depolarization. Compared to permethrin, 1 µM dinotefuran induces a persistent enhancement of spontaneous activity. Interestingly, at extrasynaptic level, using dorsal unpaired median neurons and Kenyon cells, we found that combination of both 1 µM dinotefuran and permethrin resulted in an increase of the mixture-induced current amplitudes. Pretreatment with 1 µM dinotefuran strongly decreases the currents whereas permethrin induces a time-dependent inhibition. These data demonstrate that the combination of dinotefuran and permethrin enhances the effect of dinotefuran.
Assuntos
Neurônios Colinérgicos/efeitos dos fármacos , Guanidinas/administração & dosagem , Inseticidas/administração & dosagem , Neonicotinoides/administração & dosagem , Nitrocompostos/administração & dosagem , Permetrina/administração & dosagem , Transmissão Sináptica/efeitos dos fármacos , Animais , Neurônios Colinérgicos/fisiologia , Baratas , Relação Dose-Resposta a Droga , Sinergismo Farmacológico , Insetos , Masculino , Transmissão Sináptica/fisiologiaRESUMO
BACKGROUND: Cystoisospora suis causes diarrhoeal disease and reduced weight gain in suckling piglets, and a toltrazuril-based oral suspension is available for treatment. Recently a combinatorial product with toltrazuril plus iron has been developed for parenteral application. In this study we compared the efficacy of the injectable product with the oral suspension against experimentally induced piglet cystoisosporosis. METHODS: In a randomised controlled study, three groups of piglets (n = 10-13) were treated either with a fixed dose of 45 mg toltrazuril + 200 mg gleptoferron i.m. per piglet (Forceris®) on the second day of life (study day 2; SD 2) or with 20 mg toltrazuril/kg body weight as an oral suspension (Baycox® 5%) on SD 4 or left untreated (Control group). The Baycox® and the Control group received 200 mg of iron dextran/piglet on SD 2. All piglets were infected with 1000 sporulated C. suis oocysts on SD 3. Faecal samples were taken daily from SD 7 to SD 20 to determine faecal consistency, oocyst shedding and other diarrhoeal pathogens. Body weight was recorded on SD 1 and then weekly until SD 29. Animals were observed daily for general health and after treatment for possible adverse events. RESULTS: In the Control group all animals shed oocysts for 3.1 days on average and all animals showed diarrhoea for an average of five days. Excretion peaked on SD 9 (max. 48,618 oocysts per gram of faeces). Treatment with Forceris® completely suppressed oocyst excretion. In the Baycox® group, low levels of excretion could be detected. Diarrhoea was reduced to single piglets in the treated groups. Body weight development was reduced in the Control group compared to the treated groups. Enteropathogenic bacteria (Escherichia coli, Clostridium perfringens) could be detected. All parameters related to oocyst excretion, faecal consistency and weight gain were significantly improved in the treated groups compared to the Control group without significant differences between the treated groups. Both products were safe to use. CONCLUSIONS: Treatment with both the injectable (Forceris®) and the oral (Baycox®) formulation of toltrazuril in the prepatent period were safe and highly effective against experimental infection with C. suis in newborn piglets.
Assuntos
Coccidiose/veterinária , Coccidiostáticos/administração & dosagem , Complexo Ferro-Dextran/administração & dosagem , Sarcocystidae/efeitos dos fármacos , Doenças dos Suínos/tratamento farmacológico , Triazinas/administração & dosagem , Administração Intravenosa , Administração Oral , Animais , Animais Recém-Nascidos , Peso Corporal , Coccidiose/tratamento farmacológico , Coccidiose/patologia , Diarreia/tratamento farmacológico , Diarreia/patologia , Diarreia/veterinária , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Sarcocystidae/isolamento & purificação , Suínos , Resultado do TratamentoRESUMO
Iron-deficiency anaemia (IDA) is a serious health problem in neonatal piglets and is controlled by routine application of iron in various formulations. The efficacy and safety of two iron-containing products for the prevention of IDA in suckling piglets were compared in a randomised, parallel study. Newborn piglets were treated with 200 mg iron supplied by intramuscular injection in the neck as either Forceris (gleptoferron; n=13) or Uniferon 200 (iron dextran; n=12) 24-48 hours after birth. Blood samples were collected before and after treatment (2nd, 18th and 31st day of life) for complete haematology. The treatments were well tolerated with only mild transient swelling observed in two piglets (Forceris group). Piglets treated with Forceris had significantly higher haemoglobin, haematocrit, mean corpuscular volume and haemoglobin concentration values, as well as significantly higher plasma iron and transferritin saturation and a lower total iron binding capacity than those treated with Uniferon. No animals in the Forceris group but 17 per cent of piglets in the Uniferon group had haemoglobin levels <9 g/dl after treatment, indicating anaemia. These results suggest that both products were safe and effective in the prophylaxis of IDA in piglets, and that Forceris was superior to Uniferon in preventing IDA in piglets.
RESUMO
BACKGROUND: The cat flea, Ctenocephalides felis felis (C. felis), is a cosmopolitan hematophagous ectoparasite, and is considered to be the most prevalent flea species in both Europe and the USA. Clinical signs frequently associated with flea bites include pruritus, dermatitis and in severe cases even pyodermatitis and alopecia. Ctenocephalides felis is also a vector for several pathogens and is an intermediate host for the cestode Dipylidium caninum. Treatment of cats with a fast-acting pulicide, that is persistently effective in protecting the animal against re-infestation, is therefore imperative to their health. In addition, a rapid onset of activity ("speed of kill") may also reduce the risks of disease transmission and flea allergic dermatitis. The aim of this study was to evaluate the in vitro insecticidal activity and potential synergism between dinotefuran and fipronil against C. felis. A further aim was to evaluate the onset of activity and residual speed of kill of the combination in vivo on cats artificially infested with C. felis. METHODS: In the first study, the insecticidal activity of dinotefuran and fipronil separately and dinotefuran/fipronil (DF) in combination, at a fixed ratio (2:1), was evaluated using an in vitro coated-vial bioassay. In the second study, the onset of activity against existing flea infestations and residual speed of kill of DF against artificial flea infestations on cats was assessed in vivo. Onset of activity against existing flea infestations was assessed in terms of knock-down effect within 2 h post-treatment and onset of speed of kill assessed at 3 h, 6 h and 12 h post-treatment. Residual speed of kill was evaluated 6 h and 48 h after infestation, over a period of six weeks post-treatment. RESULTS: In vitro results revealed that the DF combination was synergistic and more potent against fleas than either compound alone. The combination also proved effective when tested in vivo. Efficacy was > 97% [geometric mean (GM) and arithmetic mean (AM)] at 3 h after treatment, and ≥ 99.8% (GM and AM) at 6 h and 12 h post-treatment. At 6 h after flea re-infestations, the efficacy of DF remained ≥ 90.8% (GM and AM) for up to 28 days, and at 42 days post-treatment persistent efficacy was still ≥ 54.3% (GM and AM). At 48 h after flea re-infestations, DF remained almost fully effective for up to 28 days, with efficacies ≥ 99.4% (GM and AM) and was persistently ≥ 93.0% (GM and AM) effective for up to 42 days post-treatment. CONCLUSIONS: The combination of dinotefuran and fipronil in a single formulation exhibited strong synergistic insecticidal activity against C. felis in vitro, and also proved effective on artificially infested cats. This activity had a rapid onset that persisted for 6 weeks against re-infestations of C. felis on cats. The rapid curative insecticidal effect was observed as early as 3 h after treatment, and as early as 6 h after re-infestations for up to 6 weeks post-treatment. The insecticidal activity profile of DF makes it an optimal candidate for the protection of cats against flea infestations, and possibly also associated diseases.
Assuntos
Doenças do Gato/tratamento farmacológico , Ctenocephalides/efeitos dos fármacos , Sinergismo Farmacológico , Infestações por Pulgas/veterinária , Guanidinas/administração & dosagem , Inseticidas/administração & dosagem , Neonicotinoides/administração & dosagem , Nitrocompostos/administração & dosagem , Pirazóis/administração & dosagem , Animais , Doenças do Gato/parasitologia , Gatos , Ctenocephalides/fisiologia , Infestações por Pulgas/tratamento farmacológico , Guanidinas/farmacologia , Inseticidas/farmacologia , Neonicotinoides/farmacologia , Nitrocompostos/farmacologia , Pirazóis/farmacologia , Análise de Sobrevida , Resultado do TratamentoRESUMO
Since the 1950s, the chemotherapy of animal African trypanosomosis in cattle has essentially relied on only two compounds: isometamidium chloride (ISM), a phenanthridine, and diminazene aceturate, an aromatic diamidine. The commercial formulations of ISM, including Veridium(®) and Samorin(®), are a mixture of different compounds: ISM is the major component, mixed with the red isomer, blue isomer and disubstituted compound. To investigate the pharmacological effects of these individual compounds ISM, the blue and red isomers and the disubstituted compound were synthesised and purified by HPLC. The activity of each compound was analysed both in vitro, and in mice in vivo. For the in vitro analysis, a drug sensitivity assay was developed in 96-well tissue culture plates to determine the effective concentration which killed 50% of trypanosome population within 48 h of drug exposure (IC50). All compounds tested in vitro possessed trypanocidal activity, and purified ISM was the most active. Veridium(®) and Samorin(®) had similar IC50 values to purified ISM for both Trypanosoma congolense and Trypanosoma brucei brucei. The disubstituted compound had the highest IC50 values whereas intermediate IC50 values were obtained for the blue and red isomers. In vivo, single-dose tests were used to evaluate the trypanocidal and prophylactic activity against T. congolense. Interestingly, the prophylactic effect two months post treatment was as efficient with ISM, Veridium(®), Samorin(®) and the disubstituted compound at the highest dose of 1mg/kg whereas the red and blue isomers both showed much lower prophylactic activity. This study on T. congolense implies that it is necessary to limit the quantity of the blue and red isomers in the commercial mixture. Finally, the in vitro sensitivity assay may be useful for screening new trypanocides but also for the testing and detection of resistant trypanosome isolates.
Assuntos
Fenantridinas/farmacologia , Tripanossomicidas/farmacologia , Trypanosoma brucei brucei/efeitos dos fármacos , Trypanosoma congolense/efeitos dos fármacos , Animais , Feminino , Dose Letal Mediana , Camundongos , Testes de Sensibilidade Parasitária , Fenantridinas/uso terapêutico , Tripanossomicidas/uso terapêutico , Tripanossomíase/tratamento farmacológicoRESUMO
INTRODUCTION: Animal African trypanosomiasis (AT) is treated and controlled with homidium, isometamidium and diminazene, whereas human AT is treated with suramin, pentamidine, melarsoprol and eflornithine (DFMO), or a combination of DFMO and Nifurtimox. Monotherapy can present serious side effects, for example, melarsoprol, the more frequently used drug that is effective for both hemolymphatic and meningoencephalic stages of the disease, is so toxic that it kills 5% of treated patients. These treatments are poorly efficient, have a narrow safety index and drug resistance is a growing concern. No new drug has been developed since the discovery of DFMO in the 1970s. There is a pressing need for an effective, safe drug for both stages of the disease, and recent research is focused on the development of new formulations in order to improve their therapeutic index. AREAS COVERED: This review shows the potential interest of using nanoparticulate formulations of trypanocidal drug to improve parasite targeting, efficacy and, potentially, safety while being cost-effective. EXPERT OPINION: The design of drug formulations relevant to the treatment of AT must include a combination of very specific properties. In summary, the drug delivery system must be compatible with the physicochemical properties of the drug (charge, lipophilicity and molecular mass) in order to allow high drug payloads while being biocompatible for the patient.
Assuntos
Sistemas de Liberação de Medicamentos/métodos , Tripanossomicidas/administração & dosagem , Tripanossomíase Africana/tratamento farmacológico , Animais , Preparações de Ação Retardada , Portadores de Fármacos/química , Humanos , Lipossomos , Nanopartículas/química , Tripanossomicidas/efeitos adversos , Tripanossomicidas/uso terapêuticoRESUMO
There is a real need to develop new therapeutic strategies for African trypanosomiasis infections. In our study, we developed a new drug delivery system of diminazene (DMZ), a trypanocidal drug registered for veterinary use. This drug candidate presents a limited efficacy, a poor affinity for brain tissue and instability. The development of colloidal formulations based on a porous cationic nanoparticle with an oily core ((70)DGNP(+)), has potentially two advantages: stabilization of the drug and potential targeting of the parasite. We analyzed two processes of drug loading: in process (DMZ was added during the preparation of (70)DGNP(+) at 80 °C) and post-loading (DMZ was mixed with a (70)DGNP(+) solution at room temperature). Poor stability of the drug was observed using the in process technique. When using the post-loading technique over 80% drug entrapment efficiency was obtained at a ratio of DMZ:phospholipids (wt:wt) < 5%. Moreover, DMZ loaded into (70)DGNP(+) was found to be protected against oxidation and was stable for at least six months at 4 °C. Finally, in vitro tests on T.b. brucei showed an increased efficacy of DMZ loaded in (70)DGNP(+).